Table 2. Correlation analysis of FGF21 with clinical variables.
| Variables | rs | P value |
|---|---|---|
| Demographic data | ||
| Male, n (%) | −0.022 | 0.681 |
| Age (years) | 0.235 | 0.000 |
| Hypertension, n (%) | 0.071 | 0.187 |
| Diabetes mellitus, n (%) | 0.098 | 0.066 |
| Atrial fibrillation, n (%) | 0.017 | 0.758 |
| Laboratory data | ||
| Total cholesterol (mmol/L) | −0.078 | 0.148 |
| Triglyceride (mmol/L) | 0.017 | 0.747 |
| LDL-C (mmol/L) | 0.220 | 0.000 |
| HDL-C (mmol/L) | −0.145 | 0.007 |
| Uric acid (µmol/L) | −0.038 | 0.481 |
| Creatinine (µmol/L) | 0.075 | 0.160 |
| Troponin I (ng/ml) | 0.357 | 0.000 |
| NT-proBNP (pg/ml) | 0.749 | 0.000 |
| Echocardiographic data | ||
| Pulmonary pressure (mmHg) | 0.008 | 0.885 |
| Mitral regurgitation | 0.017 | 0.760 |
| LAD (mm) | 0.080 | 0.885 |
| IVST (mm) | −0.107 | 0.051 |
| LVPWT (mm) | −0.064 | 0.245 |
| LVEDD (mm) | 0.118 | 0.031 |
| LVESD (mm) | 0.137 | 0.012 |
| LVEDV (ml) | 0.096 | 0.074 |
| LVESV (ml) | 0.113 | 0.035 |
| LVM (g) | −0.017 | 0.751 |
| LVEF (%) | −0.127 | 0.021 |
| Multiple coronary lesions, n (%) | −0.022 | 0.685 |
Note:
STEMI, ST segment elevation myocardial infarction; FGF21, fibroblast growth factor 21; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; NT-proBNP, N-terminal proB-type natriuretic peptide; LAD, left atrial dimension; IVST, interventricular septal wall thickness; LVPWT, left ventricular posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular systolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVEF, left ventricular ejection fraction.